Fig. 8

Hedgehog pathway disruption reduces fli1:EGFP expression at doses that cause craniofacial malformations. (a) Stacked bar graph showing severity scoring of embryos exposed the potent Hedgehog pathway inhibitor BMS?833923. Embryos were exposed from 6?24 hpf and stained at 5 dpf. Number of embryos for each severity are shown (white = apparently normal, light gray = mild, dark gray = moderate, black = severe). (b) Collapsed data showing frequency of malformations for each treatment group. Bar graph of frequency of malformations following ethanol exposure. Statistics = Fischer's exact test for each control?treatment group comparison. (c) Column graph showing fli1:EGFP fluorescence measurement for each embryo (open circles). Black bars show mean fluorescence for each group ± SEM. Sample sizes: control n = 24; 1.56 ?M BMS n = 24; 3.125 ?M BMS n = 24; 6.25 ?M BMS n = 24; and 12.5 ?M BMS n = 24. Statistic: two?tailed ANOVA with Tukey's multiple comparison's correction between all groups. * = p < .05, *** = p < .001, **** p < .0001. (d) Images of 5 dpf embryos stained with alcian blue (cartilage) and alizarin red (bone) showing BMS?induced craniofacial defects. RFU = relative fluorescence units. BMS = BMS?833923, Hedgehog pathway inhibitor standard